UroGen Pharma URGN Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Net margin | -139.8%+0.5pp | -140.4%-16.7pp | -123.6%+47.0pp | -170.6%+60.1pp | |
| Free cash flow margin | -148.2%-40.9pp | -107.4%-14.8pp | -92.6%+43.9pp | -136.4%+41.8pp | |
| Returns | |||||
| Return on assets | -63.1%-8.5pp | -54.7%+10.5pp | -65.1%+20.8pp | -86%+5.7pp | |
| Efficiency | |||||
| Asset turnover | 0.5×+0.1× | 0.4×-0.1× | 0.5×0.0× | 0.5×+0.1× | |
| Liquidity | |||||
| Current ratio | 4×-2.0× | 6×+0.6× | 5.4×0.0× | 5.4×+0.3× | |
| Quick ratio | 3.7×-2.2× | 5.8×+0.6× | 5.2×0.0× | 5.2×+0.3× | |
| Cash ratio | 2.4×-1.4× | 3.7×+0.7× | 3×+0.7× | 2.3×+0.3× | |
| Leverage | |||||
| Debt-to-assets | 0.6×+0.2× | 0.4×-0.1× | 0.6×-0.2× | 0.7×+0.7× | |
| Valuation | |||||
| Market capitalization | $1.1B+144% | $449.42M-17.1% | $541.95M+165% | $204.81M-3.9% | |
| Enterprise value | $1.12B+177% | $402.93M-26.5% | $548.01M+120% | $249.46M+46.4% | |
| Price / sales | 10×+5.0× | 5×-1.6× | 6.6×+3.4× | 3.2×-1.3× | |
| EV / sales | 10.2×+5.7× | 4.5×-2.2× | 6.6×+2.7× | 3.9×+0.3× | |
| Free cash flow yield | -14.8%+6.8pp | -21.6%-7.5pp | -14.1%+28.7pp | -42.9%-2.7pp | |
| Earnings yield | -14%+14.2pp | -28.2%-9.4pp | -18.9%+34.7pp | -53.6%-1.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are UroGen Pharma's profit margins?
- UroGen Pharma (URGN) runs a 89.7% gross margin and a -329.7% operating margin, with a -94.8% net margin.
- Where do UroGen Pharma's ratios come from?
- Every ratio is computed from UroGen Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.